



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
Group Art Unit 1617

1617  
TFW \$

Patent Application of

Richard B. Mazess

Application No. 09/995,911

Confirmation No.: 4126

Filed: November 28, 2001

Examiner: Leonard M. Williams

"TREATMENT OF  
HYPERPROLIFERATIVE DISEASES  
USING ACTIVE VITAMIN D  
ANALOGUES"

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 CFR §1.97(c)

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The Examiner's attention is directed to the references which are listed on the attached Form PTO/SB/08A and/or PTO/SB/08B and copies of non-U.S. patent references are attached. This Statement is also being accompanied by a check in payment of the \$180.00 fee required under 37 CFR §1.17(p). Please charge or credit Deposit Account No. 50-0842 with any shortage or overpayment of the required fee.

Citation of these references is respectfully requested.


12/23/2005 DTESS1 00000097 09995911

01 FC:1806

180.00 OP

No concession is made that these documents are prior art, and Applicant expressly reserves the right to antedate the documents as may be appropriate.

Respectfully submitted,




Jeffrey D. Peterson  
Reg. No. 49,038

File No. 017620-9335

Michael Best & Friedrich LLP  
One South Pinckney Street  
P. O. Box 1806  
Madison, WI 53701-1806  
608.257.3501

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/995,911
				Filing Date	November 28, 2001
				First Named Inventor	Richard B. Mazess
				Group Art Unit	1617
				Examiner Name	Leonard M. Williams
Sheet	1	of	1	Attorney Docket Number	017620-9335



U.S. PATENT DOCUMENTS				
Examiner Initials		U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
<i>Ln</i>		4,686,104	Bockman et al.	8/1987
		5,264,184	Aysta et al.	11/1993
		5,300,687	Schwender	4/1994
		5,527,524	Tomalia et al.	6/1996
		5,547,947	Dore et al.	8/1996
		6,395,784	Ryono	5/2002
		6,566,353	Bishop et al.	5/2003
		6,573,256	Bishop et al.	6/2003
		6,680,309	Bishop et al.	1/2004
		2003/0207810	Bishop	11/2003
<i>Ln</i>		2004/0023934	Bishop	1/2004

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
<i>Ln</i>	WO	90/01321	Bone Care International, Inc.	2/1990		
<i>Ln</i>	WO	98/29123	Bone Care International, Inc.	7/1998		

Examiner Signature	<i>[Signature]</i>	Date Considered	1/6/2006
--------------------	--------------------	-----------------	----------


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

**DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Application Number	09/995,911	
			Filing Date	November 28, 2001	
			First Named Inventor	Richard B. Mazess	
			Group Art Unit	1617	
			Examiner Name	Leonard M. Williams	
Sheet	1	of	3	Attorney Docket Number	017620-9335



OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
Jmw	COHEN-SOLAL, M.E., et al., "1,25 Dihydroxyvitamin D and dexamethasone decrease in vivo walker carcinoma growth, but not parathyroid hormone related protein secretion," Horm. Metab. Res. (1995) 27:403-407
	EL ABDAIMI, K. et al, "Reversal of hypercalcemia with the vitamin D analogue EB1089 in a human model of squamous cancer," Cancer Research (1999) 59:3325-3328
	EL ABDAIMI, K. et al. "Expression and regulation of parathyroid hormone-related peptide in normal and malignant melanocytes," Am. J. Physiol. Cell Physiol. (1999) 279(4):C1230-1238
	ENDO, K. et al., "1,25-dihydroxyvitamin D3 as well as its analogue OCT lower blood calcium through inhibition of bone resorption in hypercalcemic rats with continuous parathyroid hormone-related peptide infusion," J. Bone and Min. Res. (2000) 15(1):175-181
	ENDO, K. et al., "Evidence for the uptake of a vitamin D analogue (OCT) by a human carcinoma and its effect of suppressing the transcription of parathyroid hormone-related peptide in vivo," J. Biol. Chem. (1994) 269(51):32693-32699
	ESBRIT, P. et al., "Parathyroid hormone-related protein as a renal regulatory factor: from vessels to glomeruli and tubular epithelium," <a href="http://www.uninet.edu/cin2000/conferences/bosch/bosch.html">http://www.uninet.edu/cin2000/conferences/bosch/bosch.html</a>
	FALZON, M. and AONG, J., "The noncalcemic vitamin D analogs EB1089 and 22-oxacalcitriol suppress serum-induced parathyroid hormone-related peptide expression in a lung cancer cell line," Endocrinology (1998) 139(3):1046-1053
Jmw	Goodman and Gilman's The Pharmacological Basis of Therapeutic, 7th edition, 1573-1580


Examiner Signature		Date Considered	1/8/2006
--------------------	--	-----------------	----------

EXAMINER: Initial/reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.  
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Application Number	09/995,911	
			Filing Date	November 28, 2001	
			First Named Inventor	Richard B. Mazess	
			Group Art Unit	1617	
			Examiner Name	Leonard M. Williams	
			Attorney Docket Number	017620-9335	
Sheet	2	of	3		




OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
Jr		HAQ, M. et al., "A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo," J. Clin. Invest. (1993) 91:2416-2422
		HOLICK, M.F. et al., Science (1973) 180:190-191
		JOHNSTON, S.R. and HAMMOND, P.J., "Elevated serum parathyroid hormone related protein and 1,25-dihydroxycholecalciferol in hypercalcaemia associated with adult T-cell leukaemia-lymphoma," Postgrad Med. J. (1992) 68(803) Abstract
		JONES, G. et al., Biochemistry (1975) 14:1250-1256
		KREMER, R. et al., "Reversal of hypercalcemia with the vitamin D analog EB1089 in a human model of squamous cancer," J. Bone Mineral Research, ASBMR 18th Annual Meeting (1996) 289
		LUPARELLO, C. et al., "Use of M-MLV RT, Rnase H-, point mutant for mRNA-differential display analysis of parathyroid hormone-related peptide (PTHrP) - treated breast carcinoma cells," Promega eNotes (2001) 1-7
		MANTELL, D.J. et al., "1alpha,25-dihydroxyvitamin D3 inhibits angiogenesis in vitro and in vivo," Circulation Research (2000) 214-220
		MOTELLON, J.L. et al., "Parathyroid hormone-related protein, parathyroid hormone, and vitamin D in hypercalcemia of malignancy," Clinica Chimica Acta (2000) 290:189-197
		OGATA, E., "Parathyroid hormone-related protein as a potential target for cancer-associated morbidity," Supp. Cancer (2000) 2909-2911
Examiner Signature		Date Considered 1/8/2003

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	09/995,911	
			Filing Date	November 28, 2001	
			First Named Inventor	Richard B. Mazess	
			Group Art Unit	1617	
			Examiner Name	Leonard M. Williams	
Sheet	3	of	3	Attorney Docket Number	017620-9335



OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
LM		SATO, K. et al., "Increased 1,25-(OH)2D2 concentration in a patient with malignancy-associated hypercalcemia receiving intravenous hyperalimentation inadvertently supplemented with vitamin D2," Intern. Med. (1993) 32(11):886-890
LM		TANIGUCHI, F. et al., "Successful management of humoral hypercalcemia of malignancy in a patient with ovarian cancer," Yonago Acta Medica (2000) 43:81-86
LM		WINGTON, D.P. et al., "Combination study of 1,24(s)-dihydroxyvitamin D2 and chemotherapeutic agents on human breast and prostate cancer cell lines," Anticancer Research (2004) 24:2905-2912

Examiner Signature		Date Considered	1/6/2006
-----------------------	--	--------------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.